TuHURA Biosciences, Inc. (NASDAQ:HURA) Stock Has Consensus Price Target of $9.00 According to Analysts

TuHURA Biosciences, Inc. (NASDAQ:HURA) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $9.00.

A number of brokerages recently commented on HURA. Citizens Jmp reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of TuHURA Biosciences in a research note on Tuesday, August 18th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of TuHURA Biosciences in a research report on Tuesday, October 27th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, October 15th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Fifth Third Bancorp bought a new stake in TuHURA Biosciences in the third quarter valued at approximately $1,095,000. Squarepoint Ops LLC bought a new position in shares of TuHURA Biosciences during the 2nd quarter worth approximately $81,000. HighTower Advisors LLC increased its holdings in shares of TuHURA Biosciences by 42.5% during the 2nd quarter. HighTower Advisors LLC now owns 30,151 shares of the company’s stock worth $71,000 after acquiring an additional 8,999 shares during the last quarter. Two Sigma Securities LLC acquired a new position in shares of TuHURA Biosciences during the 2nd quarter worth approximately $33,000. Finally, Hsbc Holdings PLC acquired a new position in shares of TuHURA Biosciences during the 2nd quarter worth approximately $69,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Stock Up 1.2%

Shares of NASDAQ:HURA opened at $1.63 on Friday. TuHURA Biosciences has a one year low of $0.41 and a one year high of $3.43. The company has a 50 day moving average of $1.98 and a 200-day moving average of $1.98. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.18 and a quick ratio of 0.18. The stock has a market cap of $103.88 million, a price-to-earnings ratio of -3.02 and a beta of -0.23.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. On average, sell-side analysts forecast that TuHURA Biosciences will post -0.57 earnings per share for the current year.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.